Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | PKM | P14618 | 3/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | XIAP | P98170 | 1/20 | 0.45 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30617863 | 1.00 | KMT2A (0.63) | KMT2ANPC1RAB9APKMALOX15 | |
| SCHEMBL798331 | 0.79 | KMT2A (0.48) | KMT2ANPC1RAB9APKMRNASEH1 | |
| SCHEMBL29965051 | 0.79 | KMT2A (0.48) | KMT2ANPC1RAB9APKMRNASEH1 | |
| Diftalone SCHEMBL35351 | 0.77 | KMT2A (1.00) | KMT2ANPC1RAB9APKMALOX15 | |
| Diftalone SCHEMBL29644941 | 0.77 | KMT2A (1.00) | KMT2ANPC1RAB9APKMALOX15 | |
| SCHEMBL2381204 | 0.74 | KMT2A (0.63) | KMT2ANPC1RAB9APKMALOX15 | |
| SCHEMBL3169575 | 0.74 | KMT2A (0.63) | KMT2ANPC1RAB9APKMALOX15 | |
| SCHEMBL22021647 | 0.74 | KMT2A (0.63) | KMT2ANPC1RAB9APKMALOX15 | |
| SCHEMBL31019490 | 0.74 | KMT2A (0.63) | KMT2ANPC1RAB9APKMALOX15 | |
| SCHEMBL19117596 | 0.74 | KMT2A (0.63) | KMT2ANPC1RAB9APKMALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102911109-B | Preparation method of 6-amino-5-fluorine-1-isoindolinone | UNIV SHANXI MEDICAL | 2014-01-15 | — | — | CN | claimed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
| CN-108697684-A | The conditioning agent of chemokine receptors | 凯莫森特里克斯股份有限公司 | 2018-10-23 | — | — | CN | disclosed |
| CN-108601766-A | Cxcr2 inhibitor | 凯莫森特里克斯股份有限公司 | 2018-09-28 | — | — | CN | disclosed |
| CN-108368053-A | Substituted benzazepine derivatives as antibacterial compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2018-08-03 | — | — | CN | disclosed |
| CN-105530932-A | Primary carboxamides as BIK inhibitors | ABBVIE INC | 2016-04-27 | — | — | CN | disclosed |
| CN-102911109-B | Preparation method of 6-amino-5-fluorine-1-isoindolinone | UNIV SHANXI MEDICAL | 2014-01-15 | — | — | CN | disclosed |
| US-8084620-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, FLT3, JAK1 | KMT2A 561/4885NPC1 3728/4885RAB9A 1788/4885 |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | KMT2A 4282/4885NPC1 89/4885RAB9A 1472/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | KMT2A 4282/4885NPC1 89/4885RAB9A 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.